145 related articles for article (PubMed ID: 35924504)
1. [Life-threatening flare of an underlying «paraneoplastic» dermatomyositis in a patient with lung adenocarcinoma treated with anti-PD-1 pembrolizuma].
Chauveheid F; von Frenckell C; Colin G; Deflandre E; Piette Y; Duysinx B; Bianchi E; Malaise M; Malaise O
Rev Med Liege; 2022 Jul; 77(7-8):462-467. PubMed ID: 35924504
[TBL] [Abstract][Full Text] [Related]
2. Anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: A case report.
Osaki M; Tachikawa R; Ohira J; Hara S; Tomii K
Invest New Drugs; 2021 Feb; 39(1):251-255. PubMed ID: 32651759
[TBL] [Abstract][Full Text] [Related]
3. Paraneoplastic dermatomyositis appearing after nivolumab therapy for gastric cancer: a case report.
Shibata C; Kato J; Toda N; Imai M; Fukumura Y; Arai J; Kurokawa K; Kondo M; Takagi K; Kojima K; Ohki T; Seki M; Yoshida M; Suzuki A; Tagawa K
J Med Case Rep; 2019 Jun; 13(1):168. PubMed ID: 31153385
[TBL] [Abstract][Full Text] [Related]
4. Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.
Marano AL; Clarke JM; Morse MA; Shah A; Barrow W; Selim MA; Hall RP; Cardones AR
Br J Dermatol; 2019 Sep; 181(3):580-583. PubMed ID: 30244487
[TBL] [Abstract][Full Text] [Related]
5. Comparative analysis of immunotherapy responses in small cell lung cancer patients with dermatomyositis.
Kim SY; Kim DK; Choi SY; Chung C
Thorac Cancer; 2024 Mar; 15(8):672-677. PubMed ID: 38352989
[TBL] [Abstract][Full Text] [Related]
6. A Rare Case of Pembrolizumab-Induced Dermatomyositis in a Patient with Cancer of Unknown Primary Origin.
Takatsuki K; Yanagihara T; Egashira A; Ogo N; Yoshizawa S; Sunami S; Asoh T; Maeyama T
Am J Case Rep; 2021 Apr; 22():e930286. PubMed ID: 33903584
[TBL] [Abstract][Full Text] [Related]
7. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC; Liu Y; Xie C; Cao BS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
[TBL] [Abstract][Full Text] [Related]
8. A case of successful pembrolizumab rechallenge in a patient with non-small-cell lung cancer and grade 3 dermatomyositis.
Kartolo A; Towheed T; Mates M
Immunotherapy; 2021 Apr; 13(6):477-481. PubMed ID: 33626928
[TBL] [Abstract][Full Text] [Related]
9. Paraneoplastic dermatomyositis associated with adenocarcinoma of the lung.
Bursac DS; Sazdanic-Velikic DS; Tepavac AP; Secen NM
J Cancer Res Ther; 2014; 10(3):730-2. PubMed ID: 25313769
[TBL] [Abstract][Full Text] [Related]
10. Dermatomyositis Complicated by Digital Ischemia and Lung Adenocarcinoma in a Patient with Positive Anti-signal Recognition Particle Antibodies.
Nawata T; Kubo M; Mitsui H; Oishi K; Omoto M; Kanda T; Yano M
Intern Med; 2018 Mar; 57(6):883-886. PubMed ID: 29151514
[TBL] [Abstract][Full Text] [Related]
11. Case of dermatomyositis during treatment with pembrolizumab for lung cancer.
Hinogami H; Yamashita C; Tanaka A; Shirai H; Nakano Y; Matsuura Y
J Dermatol; 2019 Nov; 46(11):e430-e432. PubMed ID: 31215668
[No Abstract] [Full Text] [Related]
12. Fatal Autoimmune Storm After a Single Cycle of Anti-PD-1 Therapy: A Case of Lethal Toxicity but Pathological Complete Response in Metastatic Lung Adenocarcinoma.
Fuentes-Antrás J; Peinado P; Guevara-Hoyer K; Díaz Del Arco C; Sánchez-Ramón S; Aguado C
Hematol Oncol Stem Cell Ther; 2022 Mar; 15(1):63-67. PubMed ID: 32442551
[TBL] [Abstract][Full Text] [Related]
13. Anti-TIF1γ antibody-positive dermatomyositis associated with nivolumab administration in a patient with advanced oesophageal squamous cell carcinoma: A case report and literature review.
Sakurai T; Takahashi J; Komatsu T; Mitsumura H; Iguchi Y
Mod Rheumatol Case Rep; 2023 Jun; 7(2):416-421. PubMed ID: 36715286
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitor therapy in a patient with small cell lung cancer and anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis: A case report.
Kim Y; Park D; Choi SY; Chung C
Thorac Cancer; 2022 Oct; 13(19):2808-2811. PubMed ID: 35982637
[TBL] [Abstract][Full Text] [Related]
15. Disseminated intravascular coagulation in advanced lung adenocarcinoma during first-line pembrolizumab.
Alberti A; Mancin M; Cortinovis D; Bidoli P; Sala L
Immunotherapy; 2020 Jun; 12(9):629-633. PubMed ID: 32418466
[No Abstract] [Full Text] [Related]
16. Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.
Cortellini A; Buti S; Santini D; Perrone F; Giusti R; Tiseo M; Bersanelli M; Michiara M; Grassadonia A; Brocco D; Tinari N; De Tursi M; Zoratto F; Veltri E; Marconcini R; Malorgio F; Garufi C; Russano M; Anesi C; Zeppola T; Filetti M; Marchetti P; Botticelli A; Antonini Cappellini GC; De Galitiis F; Vitale MG; Sabbatini R; Bracarda S; Berardi R; Rinaldi S; Tudini M; Silva RR; Pireddu A; Atzori F; Chiari R; Ricciuti B; Iacono D; Migliorino MR; Rossi A; Porzio G; Cannita K; Ciciarelli V; Fargnoli MC; Ascierto PA; Ficorella C
Oncologist; 2019 Jun; 24(6):e327-e337. PubMed ID: 30796151
[TBL] [Abstract][Full Text] [Related]
17. A case of severe Pembrolizumab-induced neutropenia.
Barbacki A; Maliha PG; Hudson M; Small D
Anticancer Drugs; 2018 Sep; 29(8):817-819. PubMed ID: 29889673
[TBL] [Abstract][Full Text] [Related]
18. A mild form of dermatomyositis as a prodromal sign of lung adenocarcinoma: a case report.
Papakonstantinou E; Kapp A; Raap U
J Med Case Rep; 2016 Feb; 10():34. PubMed ID: 26851947
[TBL] [Abstract][Full Text] [Related]
19. Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report.
Sugano T; Seike M; Funasaka Y; Yoshida M; Takayama R; Okamura K; Nakanishi A; Tanaka T; Takeuchi S; Noro R; Minegishi Y; Kubota K; Saeki H; Gemma A
J Immunother Cancer; 2019 Feb; 7(1):59. PubMed ID: 30813943
[TBL] [Abstract][Full Text] [Related]
20. Role of IVIG in the Treatment of Autoimmune Conditions With Concurrent Immune Checkpoint Inhibitors for Metastatic Cancer.
Punekar SR; Castillo R; Sandigursky S; Cho DC
J Immunother; 2021 Oct; 44(8):335-337. PubMed ID: 34166301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
